Specifically, RALYL binds to HNRNPC to promote the splicing of MNK2 into MNK2a instead of MNK2b, which consequently activates the p38 MAPK signaling pathway and inhibits tumor proliferation in CRC. This evidence concerns the gene MKNK2 and neoplasm.